Rising Number of Pipeline Drugs to Propel Global Urology Cancer Market, Projected to Register 10.39% CAGR By 2022


Published Date : Aug 08, 2016

ALBANY, NY, Aug 08, 2016: A new market research report, titled “Global Urological Cancer Market To 2022 - Strong Growth Driven by Rising Prevalence, Increased Uptake of Hormone Therapies and Approval of Novel Biologics,” has been added by MarketResearchReports.biz to its vast collection of research studies. The 143-page research report offers a detailed reports of the urological cancer market across the globe and highlights the key opportunities and challenges in the market.

The research study throws light on the existing commercial and clinical landscape of the global urological cancer market, emphasizing on the disease prognosis, pathogenesis, diagnosis, and the therapeutics available at every stage of the condition. Furthermore, the study analyzes the pipeline of urological cancer therapeutics and categorizes it on the basis of molecule type, molecular target, and stage of development. The report presents insights regarding which drugs are expected to receive the status of blockbuster drugs in the next few years.

According to the research study, the global market for urological cancer was worth US$17.9 bn in 2015 and is projected to reach a value of US$35.9 bn by the end of 2022. This market is anticipated to register a healthy 10.39% CAGR between 2016 and 2022. At present, there are 817 products in the pipeline of urological oncology therapeutics, while key pharmaceutical companies are making efforts to develop more drugs and get it approved in order to treat the patients.

Urological cancers account for around 19.5% of the total number of cancer cases across the world. Urological cancers primarily affect the female as well as male urinary tract and reproductive organs. Among the key types of urological cancers, namely bladder, prostate, kidney, and testicle, prostate cancer is one of the most prevalent.

For Sample Copy, click here: http://www.marketresearchreports.biz/sample/sample/759626

The growing geriatric population, hereditary cancer syndromes, chronic inflammation, and growing tobacco usage are some of the key reasons projected to stimulate the growth of the global urological cancer market in the next few years. The growing geriatric demographic, coupled with the increasing prevalence of obesity, is one of the key factors accelerating the prevalence of cancer in the coming few years. As a result, the revenue growth of the overall market is estimated to increase with the rising demand for treatment of urological cancer throughout the forecast period.

Furthermore, the research report offers an in-depth reports of the key players operating in the urological cancer market across the globe and analyzes the competitive landscape of the market. A list of all the prominent players has been given in the research study along with their detailed profiles, SWOT reports, and recent developments in the overall market. The leading players mentioned in the study are AstraZeneca, Astellas, Pfizer, Novartis, Bristol-Myers Squibb, and Johnson & Johnson. The research study helps in determining the commercial opportunities in the global urological cancer market by studying the current trends in co-development and licensing deals.

To order report Call Toll Free: 866-997-4948 or send an email on sales@marketresearchreports.biz